clinical trial · NCT05704985
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
CancerSolid TumorColorectal CancerPancreas CancerNon Small Cell Lung CancerHead and Neck CancerGynecologic CancerSkin CancerDK210 (EGFR)Radiation therapyImmune checkpoint blockersChemotherapy
brief summary
This study will evaluate safety, pharmacodynamics and biomarkers of subcutaneous (SC) DK210(EGFR) given as monotherapy and in combination with immunotherapy, chemotherapy or radiation.
started
Apr 3, 2023
primary completion
Jul 1, 2025
completion
Oct 1, 2025
last updated
May 29, 2025
detailed description
This study will evaluate DK210(EGFR) as monotherapy and combination in subjects with advanced solid EGFR expressing cancers with documented progressive disease after at least one line of systemic treatment (staging performed by local standard).
official title
Dose-finding Phase 1 Trial: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Inoperable Locally Advanced and/or Metastatic EGFR+ Tumors With Progressive Disease Failing Systemic Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol